Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
5(71%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
43%
Ph phase_4
1
14%
Ph phase_2
2
29%
Ph phase_1
1
14%

Phase Distribution

1

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
2(28.6%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

7

all time

Status Distribution
Active(5)
Completed(2)

Detailed Status

Recruiting3
Completed2
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
5
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (14.3%)
Phase 22 (28.6%)
Phase 33 (42.9%)
Phase 41 (14.3%)

Trials by Status

completed229%
recruiting343%
active_not_recruiting229%

Recent Activity

5 active trials
Showing 5 of 7
recruitingphase_2

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

NCT07143968
recruitingphase_2

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

NCT07335601
completedphase_1

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

NCT07216313
recruitingphase_4

Resmiterom Efficacy & Safety in Patients With MASH

NCT07249788
active_not_recruitingphase_3

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

NCT04951219
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07143968Phase 2

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

Recruiting
NCT07335601Phase 2

Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

Recruiting
NCT07216313Phase 1

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

Completed
NCT07249788Phase 4

Resmiterom Efficacy & Safety in Patients With MASH

Recruiting
NCT04951219Phase 3

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Active Not Recruiting
NCT05500222Phase 3

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Active Not Recruiting
NCT04197479Phase 3

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7